The mechanism of resistance is not immediately clear, but recent reports have highlighted that the AML cells may not depend on BCL2 for their survival or dependency on other prosurvival BCL2 family proteins may evolve during tumor progression and after therapy (5). This evidence concerns the gene BCL2 and neoplasm.